South Korea health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
Archive — June 2024
Page 4 of 5 of this archive, newest first.
On-off cycling, and the argument from receptor biology that does not hold
The schedules in circulation, described accurately, with their evidentiary status attached.
How a release document is put together in a regulated plant
The purity figure is the least informative line on a well-constructed certificate and the only line most buyers read.
Reflux, early satiety, and the volume the stomach will accept
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
PeptideMeter result on a Tianjin mazdutide lot lands 4.3 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A supplier suspends shipping to Brazil after 4 consecutive customs detentions
The route did not close because of a rule about peptides.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
One column, one wavelength, one very large blind spot
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
Why "muscle-sparing" is a marketing term and not a measurement
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
South Korea declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
What a 39% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
Adverse events by dose, adverse events by week
Almost every figure in circulation about tolerability comes from six publications. This is what they say.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Ireland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
TFC declines, for the 8th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Who signed this, and what did they undertake by signing it
What the Journal asks when a document arrives unsigned, and what the answers have been.
A lyophilised peptide is not stable. It is slow.
We set out what the cycle does, in order, so that a reader can see which of its steps a rushed operation shortens first.
How a correct calculation becomes a wrong dose
We have catalogued what readers report, ranked by the size of the dosing error each produces.
New Zealand declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Hong Kong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
The 9-day notice: how a compounding wind-down works in Japan
The document is four pages. Three of them are about dates.
Choosing a needle for a subcutaneous peptide
A 4 mm needle at ninety degrees without a skin pinch is adequate for essentially all adults. The persistence of 12.7 mm needles in this market is habit, not reasoning.
A tested vial is evidence about a vial
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
Nigeria caps semaglutide prescribing to 12 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What an 8% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
A supplier suspends shipping to South Korea after 10 consecutive customs detentions
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Background rates, and why they matter for attribution
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
Three services, one lot, and a spread of two and a half points
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
What a 30% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What the new Turkey guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Qingdao: 14 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What we asked twenty suppliers about stability data
Storage instructions in this market are close to uniform and almost never accompanied by the study that would justify them. Uniformity is a sign of convention, not of…
Which results are findings and which are consequences of the weight loss
Three different explanations for the same abnormal number, and how to tell them apart.
JEEP declines, for the 22nd time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.